🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Bordeaux
NCT06430424 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * age \> 18 years * surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux Exclusion Criteria: * systemic therapy received for non-glioblastoma tumor
💊

What it tests

  • Relapsed glioblastoma
📍

Where

1 site
CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale
Bordeaux, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy